b'Nontargeted cancer therapy researchConclusions and outlookResistance to chemotherapy can be one of the most troublingTo prevent and treat cancer is a key driving motivation for many circumstances for cancer patients, physicians, and oncologycancer researchers. Discovery of biomarkers that can predict researchers. Tremendous heterogeneity across types of cancerscancer development and progression, as well as treatment to and patients confounds identification of cancer therapeutics forresponse, is providing researchers tools to develop improved broad use. Elucidating genetic mechanisms of chemoresistancetherapeutics. Rapid progress on novel vaccine platform may reveal valuable insight towards identifying new therapeuticdevelopment as well as personalized cancer therapy is providing targets and developing more effective therapeutic agents.those affected by or predisposed to developing cancer, a In some cancers, chemotherapeutic resistance is thought to arisenew hope to a cure or prevention. Genetic technologies such from variable expression of Notch receptors within tumors. Theas PCR, NGS, capillary electrophoresis, and microarrays are genetic mechanisms of Notch expression variability that resultenabling researchers to develop model systems to study the in chemoresistance remain elusive. Kumar et al. identified adisease, evaluate efficacy of vaccines and therapeutic agents, specific Notch ligand that drives metastasis and chemoresistanceand determine genetic markers that influence cancer onset in breast cancer. Using RT-qPCR to correlate expression levelsor response to therapy. The findings from such studies are of the Notch ligand mRNA and the ligand, they determined thatadvancing the cancer field toward individualized evaluation and combination therapy that targets both shows almost completetreatment, given the strong influence of genetics on the disease. response to doxorubicin in Notch ligandpositive tumors [19].Thermo Fisher Scientific is committed to providing cancer Cytotoxic chemistry is currently the best line of defense againstresearchers with powerful genetic solutions that enable them to triple-negative breast cancers (TNBC), which do not express thepursue the greatest expectations of precision cancer medicine, estrogen receptor, progesterone receptor, or HER2 markers thatultimately providing more personalized treatment strategies and are targets for other breast cancer therapies. Even with cytotoxicbetter patient outcomes in the future. chemotherapy, TNBC patients have poor prognosis. Broad et al.Thermo Fisher can help you achieve your most exciting cancer turned to microarray-based transcriptomics and TaqManresearch goals with a full range of cancer genomics and miRNA assays to reveal an interferon-signaling pathway that istranscriptomics solutions.associated with chemoresistance in TNBC cells. The authors suggested that inhibition of this pathway could present a newUncover cryptic cancer heterogeneity by qPCR, dPCR, NGS, or CEresearch approach to improve future outcomes in TNBC [20]. Extract precise data from limited and challenging samples such as FFPE tissue, precious solid-tumor biopsy samples, or liquid biopsies, by dPCR or qPCRObtain key insights from multiple perspectives provided by different technologiesContents 12'